Advances in Peritoneal Dialysis

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Sample volume 1
Title Markers of Inflammation Before and During Peritoneal Dialysis
Author Rosa Palomar - Fontanet, Bernardo A. Lavin - Gomez, Jose A. Quintanar - Lartundo, Maria T. Garcia - Unzueta, Maria Gago - Fraile, Monica I. Torrealba - Rodriguez, Manuel A. Arias - Rodriguez, Juan A. Gomez - Gerique
Abstract
In this study, we compared changes in inflammatory markers—C-reactive protein (CRP), pentraxin 3 (PTX3), serum component of amyloid A (SAA), and procalcitonin (PCT)—in 182 subjects: 69 from the general population (GP), 47 with CKD, 19 with an implanted intra-abdominal catheter for peritoneal dialysis (“prePD”), and 47 on peritoneal dialysis (PD). These were the results [median (95% confidence interval)] for the GP, CKD, prePD, and PD groups respectively:
• CRP: 1.40 mg/L (1.15 – 2.10 mg/L), 5.30 mg/L 
(3.04 – 8.06 mg/L), 3.33 mg/L (2.15 – 12.58 mg/L), 
7.25 mg/L (4.43 – 15.16 mg/L)
• SAA: 3.10 mg/L (2.90 – 3.53 mg/L), 7.77 mg/L 
(4.17 – 15.83mg/L), 7.30mg/L (4.81 – 10.96mg/L), 
9.14 mg/L (5.31 – 23.54 mg/L)
• PCT: 0.028 ng/mL (0.022 – 0.032 ng/mL), 
0.121 ng/mL (0.094 – 0.166 ng/mL), 0.160 ng/
mL (0.090 – 0.277 ng/mL), 0.363 ng/mL (0.222 – 
0.481 ng/mL)
• PTX3: 0.54 ng/mL (0.33–0.62 ng/mL), 0.71 ng/
mL (0.32–1.50 ng/mL), 0.56 ng/mL (0.44–1.00 ng/
mL), 1.04 ng/mL (0.65–1.56 ng/mL)
After catheter insertion, CRP showed a nonsignificant declining trend that disappeared throughout PD. The behavior of SAA was similar to that of CRP 
and was not modified by the changes induced by the start of PD. An increase in PTX3 was observed only with PD, which may be related to a local proinflammatory state caused by PD solution. We can conclude that catheter insertion for PD does not account for most of the local inflammatory changes observed in PD patients.
Citation
References
1 Mantovani A, Garlanda C, Doni A, Bottazzi B. 
Pentraxins in innate immunity: from C-reactive 
protein to the long pentraxin PTX3. J Clin Immunol 
2008;28:1–13.
2 Manfredi AA, Rovere–Querini P, Bottazzi B, Garlanda 
C, Mantovani A. Pentraxins, humoral innate immunity 
and tissue injury. Curr Opin Immunol 2008;20:538–44.
3 Bottazzi B, Vouret–Craviari V, Bastone A, et al.
Multimer formation and ligand recognition by the 
long pentraxin PTX3. Similarities and differences 
with the short pentraxins C-reactive protein 
and serum amyloid P component. J Biol Chem 
1997;272:32817–23.
4 Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin-3, a 
new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. 
Am Heart J 2008;155:75–81.
5 Boehme M, Kaehne F, Kuehne A, et al. Pentraxin 3 is 
elevated in haemodialysis patients and is associated 
with cardiovascular disease. Nephrol Dial Transplant 
2007;22:2224–9.
6 Perseus Proteomics. Perseus Proteomics, Inc. announces Collaborative Agreement for Research on 
“PTX3 as a cardiovascular risk predictor” (press 
release). Tokyo, Japan: September 18, 2007. [Available online at: www.ppmx.com/en/corporate/
news/20070918PR_E..html; cited June 27, 2011]
7 Nauta AJ, de Haij S, Bottazzi B, et al. Human renal 
epithelial cells produce the long pentraxin PTX3. 
Kidney Int 2005;67:543–53.
8 Malle E, Bollmann A, Steinmetz A, Gemsa D, 
Leis HJ, Sattler W. Serum amyloid A (SAA) protein enhances formation of cyclooxygenase metabolites of activated human monocytes. FEBS Lett 
1997;419:215–19.
9 Maury CP, Teppo A, Eklund B, Ahonen J. Serum amyloid A protein: a sensitive indicator of renal allograft 
rejection in humans. Transplantation 1983;36:501–4.
10 Harbarth S, Holeckova K, Froidevaux C, et al. 
Diagnostic value of procalcitonin, interleukin-6, 
and interleukin-8 in critically ill patients admitted 
with suspected sepsis. Am J Resp Crit Care Med 
2001;164:396–402.
11 Christ–Crain M, Jaccard–Stolz D, Bingisser R, et al. 
Effect of procalcitonin-guided treatment on antibiotic 
use and outcome in lower respiratory tract infections: 
cluster-randomised, single-blinded intervention trial. 
Lancet 2004;363:600–7.
12 Conti G, Amore A, Chiesa M, et al. Procalcitonin as 
a marker of micro-inflammation in hemodialysis. J 
Nephrol 2005;18:282–8.
13 Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory 
response in kidney diseases using procalcitonin. J 
Nephrol 2002;15:297–301.
Keywords Abdominal catheter insertion, inflammation markers, pentraxin, serum component of amyloid A
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Share
Search in articles
Statistics
Journal Published articles
APD 49
Journal Hits
APD 164390
Journal Downloads
APD 165
Total users online -